Bridging cancer biology and the patients' needs with nanotechnology-based approaches

Cancer Treatment Reviews

Volumn 40, Issue 5, 2014, Pages 626-635

  Fonseca, Nuno A ^a,b   Gregório, Ana C ^a,c   Valério Fernandes, Ângela ^a,c   Simões, Sérgio ^a,b   Moreira, João N ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cancer; Nanotechnology; PEGylated liposomes; Polymeric nanoparticles; Tumor microenvironment

Indexed keywords

LIPOSOME; NANOCARRIER; POLYMER;

CANCER CELL; CANCER THERAPY; CELL SUBPOPULATION; DRUG BIOAVAILABILITY; DRUG COMBINATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; MICELLE; NANOMEDICINE; POLYMERIZATION; RECEPTOR BINDING; REVIEW; TUMOR VASCULARIZATION;

CANCER; NANOTECHNOLOGY; PEGYLATED LIPOSOMES; POLYMERIC NANOPARTICLES; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOGENESIS; DRUG DELIVERY SYSTEMS; FEMALE; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MOLECULAR TARGETED THERAPY; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MICROENVIRONMENT;

EID: 84898421447     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.02.002     Document Type: Review

References (119)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56(2):106-130.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
3. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
4. Jordan M.A., Thrower D., Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991, 51(8):2212-2222.
5. Miller M.L., Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem Rec 2001, 1(3):195-211.
6. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229.
7. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
9. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
10. Ranganathan R., Madanmohan S., Kesavan A., Baskar G., Krishnamoorthy Y.R., Santosham R., et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomed 2012, 7:1043-1060.
11. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760.
12. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8(6):2101-2141.
13. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
14. Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 1982, 42(11):4734-4739.
15. Gabizon A., Chisin R., Amselem S., Druckmann S., Cohen R., Goren D., et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 1991, 64(6):1125-1132.
16. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006, 1(3):297-315.
17. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160(2):117-134.
18. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991, 88(24):11460-11464.
19. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991, 1070(1):187-192.
20. Sapra P., Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003, 42(5):439-462.
21. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010, 21(5):797-802.
22. Maeda H., Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev 2011, 63(3):129-130.
23. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
24. Allen T.M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991, 1068(2):133-141.
25. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54(4):987-992.
26. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012, 12(1):39-50.
27. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3):440-449.
28. Kurtz J.E., Kaminsky M.C., Floquet A., Veillard A.S., Kimmig R., Dorum A., et al. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol 2011, 22(11):2417-2423.
29. Berenson J.R., Yellin O., Chen C.S., Patel R., Bessudo A., Boccia R.V., et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol 2011, 155(5):580-587.
30. Chen P.Y., Ozawa T., Drummond D.C., Kalra A., Fitzgerald J.B., Kirpotin D.B., et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol 2013, 15(2):189-197.
31. Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., Kirpotin D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006, 66(6):3271-3277.
32. Gomes-da-Silva L.C., Simoes S., Moreira J.N. Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cell Mol Life Sci 2013.
33. Gomes-da-Silva L.C., Fonseca N.A., Moura V., Pedroso de Lima M.C., Simoes S., Moreira J.N. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 2012, 45(7):1163-1171.
34. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992, 267(26):18759-18765.
35. Gabizon A., Shiota R., Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989, 81(19):1484-1488.
36. Allen T.M., Austin G.A., Chonn A., Lin L., Lee K.C. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta 1991, 1061(1):56-64.
37. Leonard R.C., Williams S., Tulpule A., Levine A.M., Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 2009, 18(4):218-224.
38. Swenson C.E., Bolcsak L.E., Batist G., Guthrie T.H., Tkaczuk K.H., Boxenbaum H., et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003, 14(3):239-246.
39. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94(1):25-36.
40. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19(5):1444-1454.
41. Petre C.E., Dittmer D.P. Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomed 2007, 2(3):277-288.
42. Gill P.S., Espina B.M., Muggia F., Cabriales S., Tulpule A., Esplin J.A., et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995, 13(4):996-1003.
43. Kaspers G.J., Zimmermann M., Reinhardt D., Gibson B.E., Tamminga R.Y., Aleinikova O., et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013, 31(5):599-607.
44. Thomas D.A., Kantarjian H.M., Stock W., Heffner L.T., Faderl S., Garcia-Manero G., et al. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 2009, 115(23):5490-5498.
45. Thomas D.A., Sarris A.H., Cortes J., Faderl S., O'Brien S., Giles F.J., et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 2006, 106(1):120-127.
46. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965, 13(1):238-252.
47. Duncan R. Polymer conjugates for drug targeting. From inspired to inspiration!. J Drug Target 2006, 14(6):333-335.
48. Duncan R., Ringsdorf H., Satchi-Fainaro R. Polymer therapeutics-polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J Drug Target 2006, 14(6):337-341.
49. Yu M.K., Park J., Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2(1):3-44.
50. Fuertges F., Abuchowski A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J Control Release 1990, 11(1-3):139-148.
51. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2(3):214-221.
52. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1):16-20.
53. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41(7):2971-3010.
54. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25(1):55-71.
55. Levy Y., Hershfield M.S., Fernandez-Mejia C., Polmar S.H., Scudiery D., Berger M., et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr 1988, 113(2):312-317.
56. Graham M.L. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003, 55(10):1293-1302.
57. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004, 10(11):1235-1244.
58. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975, 51(1):135-153.
59. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol 1974, 23(18):2495-2531.
60. Vicent M.J., Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006, 24(1):39-47.
61. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011, 22(4):492-501.
62. Vicent M.J., Ringsdorf H., Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev 2009, 61(13):1117-1120.
63. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999, 5(1):83-94.
64. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6(9):688-701.
65. Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev 2009, 61(13):1131-1148.
66. Rademaker-Lakhai J.M., Terret C., Howell S.B., Baud C.M., De Boer R.F., Pluim D., et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004, 10(10):3386-3395.
67. Boddy A.V., Plummer E.R., Todd R., Sludden J., Griffin M., Robson L., et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005, 11(21):7834-7840.
68. Singer J.W., Baker B., De Vries P., Kumar A., Shaffer S., Vawter E., et al. Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 2003, 519:81-99.
69. Galic V.L., Wright J.D., Lewin S.N., Herzog T.J. Paclitaxel poliglumex for ovarian cancer. Expert Opin Investig Drugs 2011, 20(6):813-821.
70. Svenson S., Wolfgang M., Hwang J., Ryan J., Eliasof S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 2011, 153(1):49-55.
71. Young C., Schluep T., Hwang J., Eliasof S. CRLX101 (formerly IT-101) - a novel nanopharmaceutical of camptothecin in clinical development. Curr Bioact Compd 2011, 7(1):8-14.
72. Weiss G.J., Chao J., Neidhart J.D., Ramanathan R.K., Bassett D., Neidhart J.A., Choi C.H., Chow W., Chung V., Forman S.J., Garmey E., Hwang J., Kalinoski D.L., Koczywas M., Longmate J., Melton R.J., Morgan R., Oliver J., Peterkin J.J., Ryan J.L., Schluep T., Synold T.W., Twardowski P., Davis M.E., Yen Y. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013, 31(4):986-1000.
73. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 2008, 60(8):899-914.
74. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004, 91(10):1775-1781.
75. Hamaguchi T., Kato K., Yasui H., Morizane C., Ikeda M., Ueno H., et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007, 97(2):170-176.
76. Valle J.W., Armstrong A., Newman C., Alakhov V., Pietrzynski G., Brewer J., et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 2011, 29(5):1029-1037.
77. Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004, 10(11):3708-3716.
78. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010, 27(12):2569-2589.
79. Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007, 18(7):1159-1164.
80. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73(8):2412-2417.
81. Duncan R., Vicent M.J. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev 2013, 65(1):60-70.
82. Drummond D.C., Zignani M., Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 2000, 39(5):409-460.
83. Simoes S., Moreira J.N., Fonseca C., Duzgunes N., de Lima M.C. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004, 56(7):947-965.
84. Karanth H., Murthy R.S. PH-sensitive liposomes-principle and application in cancer therapy. J Pharm Pharmacol 2007, 59(4):469-483.
85. Ishida T., Okada Y., Kobayashi T., Kiwada H. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm 2006, 309(1-2):94-100.
86. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000, 60(5):1197-1201.
87. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001, 53(3):285-305.
88. Gaber M.H., Hong K., Huang S.K., Papahadjopoulos D. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm Res 1995, 12(10):1407-1416.
89. Gaber M.H., Wu N.Z., Hong K., Huang S.K., Dewhirst M.W., Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996, 36(5):1177-1187.
90. Poon R.T., Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 2011, 7(8):937-945.
91. Pinto A.C., Moreira J.N., Simoes S. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer. Prostate 2011, 71(1):81-90.
92. Mayer L.D., Harasym T.O., Tardi P.G., Harasym N.L., Shew C.R., Johnstone S.A., et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006, 5(7):1854-1863.
93. Feldman E.J., Lancet J.E., Kolitz J.E., Ritchie E.K., Roboz G.J., List A.F., et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011, 29(8):979-985.
94. Tardi P., Johnstone S., Harasym N., Xie S., Harasym T., Zisman N., et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33(1):129-139.
95. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346(2):85-91.
96. Tardi P.G., Dos Santos N., Harasym T.O., Johnstone S.A., Zisman N., Tsang A.W., et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 2009, 8(8):2266-2275.
97. Hamaguchi T., Matsumura Y., Nakanishi Y., Muro K., Yamada Y., Shimada Y., et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci 2004, 95(7):608-613.
98. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004, 15(3):517-525.
99. Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 2008, 346(1-2):143-150.
100. Xu L., Tang W.H., Huang C.C., Alexander W., Xiang L.M., Pirollo K.F., et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 2001, 7(10):723-734.
101. Reynolds J.G., Geretti E., Hendriks B.S., Lee H., Leonard S.C., Klinz S.G., et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012, 262(1):1-10.
102. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6(3):659-668.
103. Moura V., Lacerda M., Figueiredo P., Corvo M.L., Cruz M.E., Soares R., et al. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer. Breast Cancer Res Treat 2012, 133(1):61-73.
104. Hovanessian A.G., Soundaramourty C., Khoury D.E., Nondier I., Svab J., Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One 2010, 5(12):e15787.
105. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163(4):871-878.
106. Gomes-da-Silva L.C., Ramalho J.S., Pedroso de Lima M.C., Simoes S., Moreira J.N. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells. Eur J Pharm Biopharm 2013, 85(3 Pt A):356-364.
107. Gomes-da-Silva L.C., Fernandez Y., Abasolo I., Schwartz S., Ramalho J.S., Pedroso de Lima M.C., Simoes S., Moreira J.N. Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform. Nanomedicine (Lond) 2013, 8(9):1397-1413.
108. Gomes-da-Silva L.C., Santos A.O., Bimbo L.M., Moura V., Ramalho J.S., Lima M.C., Simoes S., Moreira J.N. Towards a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int J Pharm 2012, 434(1-2):9-19.
109. Pastorino F., Brignole C., Loi M., Di Paolo D., Di Fiore A., Perri P., et al. Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. Front Oncol 2013, 3:190.
110. Loi M., Marchio S., Becherini P., Di Paolo D., Soster M., Curnis F., Brignole C., Pagnan G., Perri P., Caffa I., Longhi R., Nico B., Bussolino F., Gambini C., Ribatti D., Cilli M., Arap W., Pasqualini R., Allen T.M., Corti A., Ponzoni M., Pastorino F. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 2010, 145(1):66-73.
111. Shi J., Xiao Z., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011, 44(10):1123-1134.
112. Hrkach J., Von Hoff D., Mukkaram Ali M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4(128):128ra139.
113. Chang S.S., Reuter V.E., Heston W.D., Bander N.H., Grauer L.S., Gaudin P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999, 59(13):3192-3198.
114. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31):7794-7803.
115. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006, 7(8):1041-1053.
116. Gradishar W.J. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol 2005, 3(5):348-349.
117. Montana M., Ducros C., Verhaeghe P., Terme T., Vanelle P., Rathelot P. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother 2011, 23(2):59-66.
118. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24(10):1211-1217.
119. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2012, 9(1):1-14.